Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial
| Autor: | F. Rossi, Giulio Francolini, Luis Jose Sanchez, Lorenzo Orzalesi, Icro Meattini, Stefania Pallotta, Isacco Desideri, Marco Bernini, Vieri Scotti, Lucia Di Brina, Simonetta Bianchi, Livia Marrazzo, Donato Casella, Benedetta Bendinelli, Daniela Greto, Pierluigi Bonomo, Jacopo Nori, F. Meacci, R. Simoncini, Ilaria Furfaro, Calogero Saieva, Carla De Luca Cardillo, Lorenzo Livi, Monica Mangoni |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Cancer Research
medicine.medical_specialty medicine.medical_treatment Subgroup analysis Breast Neoplasms Kaplan-Meier Estimate Breast cancer Quality of life Whole Breast Irradiation medicine Breast-conserving surgery Biomarkers Tumor Humans Neoplasm Metastasis Aged Neoplasm Staging Aged 80 and over business.industry Age Factors Partial Breast Irradiation medicine.disease Surgery Radiation therapy Treatment Outcome Oncology Female Intensity modulated radiotherapy Radiology Radiotherapy Intensity-Modulated Neoplasm Grading Radiotherapy Conformal business Follow-Up Studies |
| Zdroj: | Breast cancer research and treatment. 153(3) |
| ISSN: | 1573-7217 |
| Popis: | The purpose of this study was to report the efficacy and the safety profile on the subset of selected early breast cancer (BC) patients aged 70 years or older from a single-center phase 3 trial comparing whole breast irradiation (WBI) to accelerated partial breast irradiation (APBI) using intensity-modulated radiation therapy technique. Between 2005 and 2013, 520 patients aged more than 40 years old were enrolled and randomly assigned to receive either WBI or APBI in a 1:1 ratio. Eligible patients were women with early BC (maximum diameter 2.5 cm) suitable for breast conserving surgery. This study is registered with ClinicalTrials.gov, NCT02104895. A total of 117 patients aged 70 years or more were analyzed (58 in the WBI arm, 59 in the APBI arm). At a median follow-up of 5-years (range 3.4-7.0), the ipsilateral breast tumor recurrence (IBTR) rate was 1.9 % in both groups. No significant difference between the two groups was identified (log-rank test p = 0.96). The 5-year disease-free survival (DFS) rates in the WBI group and APBI group were 6.1 and 1.9 %, respectively (p = 0.33). The APBI group presented significantly better results in terms of acute skin toxicity, considering both any grade (p = 0.0001) and grade 2 or higher (p = 0.0001). Our subgroup analyses showed a very low rate and no significant difference in terms of IBTR, using both WBI and APBI. A significant impact on patients compliance in terms of acute and early late toxicity was shown, which could translate in a consistent improvement of overall quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink